|
Match
|
Document |
Document Title |
|
|
5425943 |
Modified tPA-containing injection composition having increased solubility
An injection composition comprises a pharmacologically effective amount of a modified tPA, 47.5 mM or more of an amino acid or a salt thereof and is improved in view of stability and solubility.
|
|
|
5425942 |
Polyfunctinal protease
The present invention provides a human polyfuctional protease chracterized in that the protease has unique enzymological and physicochemical properties:
|
|
|
5413786 |
Method of accelerating blood coagulation using a metal complex of oxidized ellagic acid
Blood coagulation is accelerated by contacting blood with an accelerator of hydrolase activity. The activation of the precursors of serine protease including Factor XII and the enzyme activity of...
|
|
|
5411885 |
Methods for tissue embedding and tissue culturing
Methods of embedding and culturing tissue employing a fibrin glue composition of 2 to 100 mg/ml fibrinogen, 1 to 200 U/ml fibrinogen-activating enzyme, and 1 to 30 mM Ca(II) compound, are disclosed.
|
|
|
5409700 |
Pharmaceutical compositions comprising modified and unmodified plasminogen activators
The present invention relates to pharmaceutical compositions comprising a combination of two different plasminogen activators which are used for the prophylaxis and therapie of thrombosis.
|
|
|
5409699 |
Compositions containing glycosylated molecules having human tissue type plasminogen activator enzymatic activity
The invention is a pharmaceutical composition containing a glycosylated protein having human tissue type plasminogen activator activity of at least 1.4 MU/ml, citrate, and at least one of a number...
|
|
|
5407673 |
Fibrinolysis and fibrinogenolysis treatment
Disclosed is a fibrinolysis and fibrinogenolysis treatment which includes parenterally introducing into the body of a human patient human plasmin in fibrinolytically and fibrinogenolytically active...
|
|
|
5405607 |
Method for preparing fibrinogen adhesive from whole blood
A process and apparatus for one-step preparation of the fibrinogen component of an adhesive is described. The fibrinogen is precipitated directly from plasma using polyethylene glycol. This permits...
|
|
|
5397704 |
Ultra-pure thrombin preparation
An ultra-pure, clear thrombin solution having a high specific activity is described as well as a method of manufacture.
|
|
|
5393666 |
Method of activating prothrombin
There is disclosed a method of activating prothrombin by means of trypsin, wherein the prothrombin is recovered from a blood or plasma fraction, treated with trypsin immobilized on a...
|
|
|
5391371 |
Use of an enzyme containing granulate in a method for production of a pelletized fodder
An enzyme containing T-granulate, coated with a coating agent comprising a high melting fat or wax, is combined with a mixture containing fodder components, and the combination is steam treated and...
|
|
|
5389538 |
Mutant human prourokinase
A mutant human prourokinase wherein a neutral amino acid in the epidermal growth factor (EGF) region of human prourokinase (human PUK) has been replaced with a basic amino acid, or an acidic amino...
|
|
|
5385732 |
Variants of tissue plasminogen activator, compositions and methods of use for same
A fibrinolytically active amino acid sequence variant of a plasminogen activator is prepared that has one or more glycosylation sites in regions that are not glycosylated in the native molecule....
|
|
|
5376633 |
Method for deactivating viruses in blood component containers
The present invention provides a method for inhibiting viral proliferation by preventing or inhibiting viral replication or killing the viruses on contact. Viral replication is prevented or...
|
|
|
5372812 |
Composition and method for acceleration of clot lysis
The present invention relates to a novel treatment for blood clots within a patient or myocardial infarction which comprises administering a hapten-binding molecule capable of preventing inhibition...
|
|
|
5366869 |
Multiple coagulation test device and method
A multiple coagulation test device has a plurality of tubes, each tube having associated coagulation detection means, and containing a treatment dosage of a coagulation enhancing agent. Whole blood...
|
|
|
5366730 |
Stabilized compositions having human tissue type plasminogen activator enzymatic activity
Pharmaceutical preparation of a protein with t-PA activity with an enzymatic activity of at least 0.25 MU/ml. and a pH value of 4.5 to 9 which contains a substance of the group citric acid,...
|
|
|
5364622 |
Methods for preventing adhesions to organs and parts of organs by application of tissue plasminogen activator and hydroxyethylcellulose hydrogel
A method for the prevention of adhesions to body organs and parts of organs caused by therapeutic intervention by applying a pharmaceutical composition of tissue plasminogen activator and an...
|
|
|
5352453 |
Compositions containing non-glycosylated human tissue type plasminogen activator
Pharmaceutical compositions containing non-glycosylated human tissue type plasminogen activator (t-PA) having enzymatic activity of at least 0.1 MU/ml are disclosed. The compositions have a pH of...
|
|
|
5352452 |
Stabilized compositions containing non-glysylated human tissue type plasminogen activator derivative K2P pro
Stabilized compositions containing a non-glycosylated human tissue type plasminogen activator derivative are disclosed. The derivative is referred to as K2P pro. The composition has enzymatic...
|
|
|
5350578 |
Inhibition of arterial thrombotic occlusion or thromboembolism
The method of preventing arterial thrombotic occlusion or thromboembolism by administering plasma-derived or recombinant produced protein C alone or in combination with a thrombolytic agent or...
|
|
|
5342616 |
Method of administering tissue plasminogen activator
The use of bolus injections of t-PA in the treatment of human beings with a thrombotic disorder.
|
|
|
5338546 |
Tissue plasminogen activator variants with decreased clearance
Biologically active tissue plasminogen activator (t-PA) variants with decreased clearance as compared to wild-type t-PA are prepared, including variants that have one or more amino acid alterations...
|
|
|
5336495 |
Use of staphylokinase for the preparation of a pharmaceutical composition for treating arterial thromboisi
The present invention relates to the use of staphylokinase for the preparation of a pharmaceutical composition for treating arterial thrombosis, such as e.g. myocardial infarction. It is...
|
|
|
5334384 |
Process for purification of streptakinase using a reducing agent
A process for the separation of streptokinase from contaminating proteins in a streptokinase-containing mixture, which comprises treating the mixture with a reducing agent to reduce disulphide...
|
|
|
5326562 |
Pharmaceutical dosage unit for treating inflammation comprising protease nexin-I
Methods and pharmaceutical compositions for treatment of inflammation and arthritis using protease nexin-I as an active ingredient are disclosed.
|
|
|
5324647 |
Fibrin coated polymer surfaces
Surfaces of polymeric materials are coated with a layer of thermally denatured fibrinogen. The fibrinogen may be treated with thrombin to produce fibrin, and additional fibrinogen and factor XIII...
|
|
|
5324514 |
Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
Disclosed are gastric acid-resistant polymer-coated digestive enzymes/ursodeoxycholate compositions, process for their preparations and methods of treating digestive disorders, treating impaired...
|
|
|
5316766 |
Thrombosis treatment with fibrinolytics and prostacyclins
The combination of a fibrinolytic and a prostacyclin analogue is very useful for thrombosis treatment, especially to avoid subsequent rethrombosis.
|
|
|
5315998 |
Booster for therapy of diseases with ultrasound and pharmaceutical liquid composition containing the same
A booster comprising a plenty of microbubbles of a gas in a liquid, e.g. about 4×10 7 cells/ml of microbubbles of a gas having a diameter of 0.1 to 100 μm in a 3 to 5% human serum albumin...
|
|
|
5308617 |
Protein heparin conjugates
A pharmaceutical composition is prepared wherein a biologically active conjugated protein is selectively conjugated to at least one heparin fragment having a terminal 2,5-anhydro-D-mannose residue...
|
|
|
5304383 |
Pharmaceutical preparation based on Lys-plasminogen
There is disclosed a pharmaceutical preparation based on Lys-plasminogen and available in the lyophilized form. This preparation contains a serine-protease inhibitor and optionally an inhibitor...
|
|
|
5304372 |
Process for preparing a human thrombin concentrate intended for therapeutic use
Process for preparing a human thrombin concentrate from the PPSB fraction of plasma that does not involve any addition of factors of animal origin to induce activation of the prothrombin to produce...
|
|
|
5302390 |
Hybrid proteins of human plasminogen and human t-PA, pharmaceutical compositions and methods of treatment
A hybrid plasminogen activator which comprises the five kringle domains of plasminogen linked to the B-chain of t-PA or u-PA via an amino acid sequence comprising, respectively, the t-PA cleavage...
|
|
|
5298255 |
Antithrombic medical material, artificial internal organ, and method for production of antithrombic medical material
An antithrombic medical material, having superposed on the surface of a substrate formed of a polymer material a polymerized protein substantially free at least from erythrocyte and leukocyte, a...
|
|
|
5296223 |
Subtilisin as an oral thrombolytic agent
There are provided thrombolytic agents suited for oral administration. The agent comprises a proteolytic enzyme of subtilisin family, such as subtilisin BPN', subtilisin Carsberg, subtilisin...
|
|
|
5296357 |
Method for the detection of plasminogen activators, their inhibitors of stimulators
The invention relates to a method for the detection of the functional activity of plasminogen activators and of their inhibitors and stimulators in biological samples, and to reagents for this method.
|
|
|
5290552 |
Surgical adhesive material
The present invention provides a surgical adhesive comprising, in an aqueous composition, fibrinogen, FXIII, collagen, thrombin, Ca 2 + and optionally, an antifibrinolytic agent. The present...
|
|
|
5288490 |
Thrombus-targeted complexes of plasminogen activator and fibrin fragments
Thrombolytic hybrids are formed as covalent or non-covalent complexes of fibrin fragments and plasminogen activator molecules. Native plasmin degradation fragments of fibrin or non-native fibrin...
|
|
|
5278144 |
Antithrombosis agents
Analogs of Factor Xa (Factor Xai) which are inactive as proteases in the prothrombinase reaction are useful in treatment of diseases characterized by thrombosis. These antithrombotic agents can be...
|
|
|
5275946 |
Thrombolytic agents with modified kringle domains
This invention relates to analogs of thrombolytic agents having a modified kringle domain. More specifically, this invention is directed to TPA type compounds wherein modifications occur in the...
|
|
|
5272076 |
Compounds and methods for treatment of thromboembolic disorders using an adduct of t-PA
The present invention provides adducts of human t-PA derivatives, which comprise a t-PA derivative that lacks the Finger, Growth Factor and Kringle 1 domains, bound to an amphipathic molecule. The...
|
|
|
5270040 |
Vectors and compounds for expression of human protein C
The present invention comprises novel DNA compounds which encode human protein C activity. A variety of eukaryotic and prokaryotic recombinant DNA expression vectors have been constructed that...
|
|
|
5258180 |
Tissue plasminogen activator having fibrin specific properties and deletion of amino acids 466-970, compositions and methods of treatment
A tissue plasminogen activator (t-PA) variant is prepared that has an amino acid deletion at positions 466 to 470 of the corresponding wild-type t-PA. This alteration renders the variant fibrin...
|
|
|
5256642 |
Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
The present invention relates to compositions comprising soluble complement receptor 1 (CR1) and a thrombolytic agent. In a specific embodiment, the thrombolytic agent is anisoylated human...
|
|
|
5252463 |
Clipsin, a chymotrypsin-like protease and method of using same
A novel M r 25,000 chymotrypsin-like protease, termed clipsin, which binds to a-1-AChy in a sodium dodecyl sulfate-resistant manner, preferentially degrades β-APP, and shows high activity for a...
|
|
|
5244676 |
Modified tissue plasminogen activator with modified glycosylation site
A modified t-PA having improved in vivo half-life is disclosed comprising in sequence a fibronectin finger-like domain F, a growth factor domain GF, a sequence of two K2 kringle regions and a...
|
|
|
5244673 |
Medicamentous form for use as an ophthalmologic, otolaryngologic, or dermatologic drug
A medicamentous form or composition with antiexudation, antiphlogistic, and antimicrobial effects in an aqueous or ointment base, suitable above all as an ophthalmologic, otolaryngologic, or...
|
|
|
5242688 |
Method of treating thromboembolic disorders by administration of diglycosylated t-PA variants
The present invention provides a method of treating thromboembolic disorders with the diglycosylated form of a tissue plasminogen activator derivative that lacks the Finger, EGF and Kringle I...
|
|
|
5240845 |
Mutated streptokinase proteins
This invention relates to a novel chemically synthesized gene including a base sequence coding for the primary amino acid sequence of natutal-type streptokinase, a corresponding plasmid...
|